as on September 18, 2025 at 1:29 am IST
Day's Low
Day's High
2.23%
Downside
3.31%
Upside
52 Week's Low
52 Week's High
87.31%
Downside
3.31%
Upside
Check Nektar Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$971.3M
EPS (TTM)
-11.0633
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-1.32
Industry PE ratio
-3.9415151515151514
P/B Ratio
0PEG Ratio
3.22
EBITDA
-137.2M
Revenue (TTM)
74.9M
Profit Margin
-163.17%
Return On Equity TTM
6206900.00%
Track how Nektar Therapeutics P/E has moved over time to understand its valuation trends.
Nektar Therapeutics in the last 5 years
Lowest (0.00x)
September 18, 2025
Industry (-3.94x)
September 18, 2025
Today (-1.32x)
September 18, 2025
Highest (0.00x)
September 18, 2025
Today’s Price to Earnings Ratio: -1.32x
Compare market cap, revenue, PE, and other key metrics of Nektar Therapeutics with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
HOLD | $971.3M | -83.12% | -1.32 | -163.17% | |
BUY | $60.5B | 248.74% | -505.15 | -12.96% | |
NA | $38.7B | NA | NA | -3.89% | |
BUY | $99.3B | 45.88% | 27.56 | 31.86% | |
BUY | $60.9B | 5.45% | 14.49 | 31.37% |
The Nektar Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Nektar Therapeutics investment value today
Current value as on today
₹2,74,757
Returns
₹1,74,757
(+174.76%)
Returns from Nektar Therapeutics Stock
₹1,70,159 (+170.16%)
Dollar Returns*
₹4,598 (+4.6%)
Based on 9 analysts
0.00%
Buy
55.56%
Hold
44.44%
Sell
Based on 9 analysts, 55.56% of analysts recommend a 'HOLD' rating for Nektar Therapeutics. Average target price of $96.17
Get share price movements and forecasts by analysts on Nektar Therapeutics.
What analysts predicted
46.91%UPSIDE
Target Price
$96.17
Current Price
$51.06
Analyzed by
9 Analysts
Target
$96.17
Nektar Therapeutics target price $96.17, a slight upside of 46.91% compared to current price of $51.06. According to 9 analysts rating.
Search interest for Nektar Therapeutics Stock has increased by 68% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:68% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
Netprofit is up for the last 2 quarters, -50.88M → -41.59M (in $), with an average increase of 22.3% per quarter
Best in 1 Year
In the last 1 year, NKTR has outperformed top 5 stocks with highest market-cap in its industry
Price Rise
In the last 3 months, NKTR stock has moved up by 493.1%
Revenue Rich
Revenue is up for the last 2 quarters, 10.46M → 11.17M (in $), with an average increase of 6.4% per quarter
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 113.4%
Organisation | Nektar Therapeutics |
Headquarters | 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 |
Industry | Health Technology |
CEO | Mr. Howard W. Robin |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Ms. Sandra A. Gardiner | CFO and Principal Financial & Accounting Officer |
Mr. Mark A. Wilson J.D. | Senior VP, Chief Legal Officer & Secretary |
Dr. Jonathan Zalevsky Ph.D. | Senior VP and Chief Research & Development Officer |
Mr. Jason Barnard | Chief Accounting Officer |
Mr. Robert Bacci | Chief People Officer and Head of Quality & Facilities |
Ms. Jennifer Ruddock | Chief Business Officer |
Dr. Brian L. Kotzin M.D. | Interim Chief Medical Officer |
Mr. Howard W. Robin | CEO, President & Director |
Nektar Therapeutics share price today is $51.06 as on at the close of the market. Nektar Therapeutics share today touched a day high of $52.75 and a low of $49.92.
Nektar Therapeutics share touched a 52 week high of $52.75 on and a 52 week low of $6.48 on . Nektar Therapeutics stock price today i.e. is closed at $51.06,which is 3.20% down from its 52 week high and 687.96% up from its 52 week low.
Nektar Therapeutics market capitalisation is $0.00T as on .
Indian investors can start investing in Nektar Therapeutics (NKTR) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Nektar Therapeutics stock (as per the Rupee-Dollar exchange rate as on ).
Based on Nektar Therapeutics share’s latest price of $51.06 as on September 18, 2025 at 1:29 am IST, you will get 0.1958 shares of Nektar Therapeutics. Learn more about
fractional shares .
Nektar Therapeutics stock has given -83.12% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?